A radiopharmaceutical is a substance that contains a small amount of radiation and is used to diagnose or treat certain diseases. It may be taken by mouth, injected, or put into the bladder or eye. Radiopharmaceuticals are not dangerous as the amount of radiation they produce is very low and has little effect on normal tissue. They can help doctors see certain parts of the body, such as the brain or bones, and they also can give information about how organs are working.
Diagnostic radiopharmaceuticals and contrast media are essential tools in a range of medical procedures. They provide an accurate diagnosis of the disease and help in early treatment. These agents are useful in determining the location and extent of the disease. They are widely used in the treatment of cancer, cardiovascular disease, neurological disorder, gastrointestinal disorder, and others.
The Diagnostic radiopharmaceuticals and contrast media are used in conjunction with an imaging device that registers the gamma rays they emit. This information is displayed on two-dimensional images or, with tomography, three-dimensional images of the organ being studied. Radioisotopes may also be used to trace blood flow through arteries or veins, to determine the amount of tissue activity, or in certain cases, to monitor the effects of a therapeutic procedure.
With ongoing advancements in medical imaging technologies and a growing focus on accurate diagnosis and treatment, the market for Diagnostic Radiopharmaceuticals and Contrast Media is projected to expand further. The global Diagnostic Radiopharmaceuticals And Contrast Media Market was valued at US$ 6,434.9 Million in 2022 and is forecast to reach a value of US$ 10,140.7 Mn by 2030 at a CAGR of 5.8% between 2023 and 2030. The rising prevalence of chronic diseases, coupled with an aging population, has also fueled the market’s growth. Additionally, the development of safer and more efficient Contrast Media formulations, along with stringent regulatory standards, has contributed to the market’s overall success. As healthcare systems continue to prioritize patient care and diagnostics, the market is set to experience continuous progress in the coming years.
Nihon Medi-Physics Co., Ltd., and Fuzionaire Radioisotope Technologies K.K., entered in a feasibility study agreement in January 2021. According to the agreement, NMP will evaluate Fuzionaire Dx’s ability for creating a new class of positron emission tomography (PET) radiopharmaceuticals.
A contrast agent is a radioactive drug that is injected into the patient to help doctors observe the functioning of organs such as the liver, heart, kidney, and lungs. Diagnostic Radiopharmaceuticals and Contrast Media helps in the diagnosis and treatment of diseases such as tumors, infections, and cardiovascular disease. Contrast agents are used in various imaging procedures such as CT, MRI, PET/CT, ultrasound, and X-ray. A small amount of the agent is absorbed by the body and its radiation decays after a short time. The procedure is non-invasive and does not involve any physical discomfort to the patients. Besides, the results of this test can be obtained very quickly. This technique is also used for guiding a surgical procedure, predicting the effects of medication and treatment, and assessing changes since a previous operation or diagnosis.
